Melanoma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Melanoma stocks.

Melanoma Stocks Recent News

Date Stock Title
May 24 BMY Terran Biosciences prepares for trials of schizophrenia drug
May 24 EVAX Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
May 23 MYGN Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23 BMY Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
May 23 EVAX Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
May 23 BMY Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
May 23 CSTL Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
May 23 BMY Does Bristol-Myers Squibb (NYSE:BMY) Have A Healthy Balance Sheet?
May 23 CSTL What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
May 23 BMY This Unpopular Dividend Stock Is a Buy
May 23 BMY Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 22 BMY Bristol-Myers Squibb snaps six days of losses, trades in the green
May 22 BMY Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M
May 22 BMY Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
May 22 BMY Pfizer to Cut Costs in Multi-Year Effort
May 22 BMY Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
May 22 BMY Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
May 22 BMY Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22 BMY Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines
May 22 BMY NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Melanoma

Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Sometimes they develop from a mole with changes such as an increase in size, irregular edges, change in color, itchiness, or skin breakdown.The primary cause of melanoma is ultraviolet light (UV) exposure in those with low levels of skin pigment. The UV light may be from either the sun or from other sources, such as tanning devices. About 25% develop from moles. Those with many moles, a history of affected family members, and who have poor immune function are at greater risk. A number of rare genetic defects such as xeroderma pigmentosum also increase risk. Diagnosis is by biopsy and analysis of any skin lesion that has signs of being potentially cancerous.Using sunscreen and avoiding UV light may prevent melanoma. Treatment is typically removal by surgery. In those with slightly larger cancers, nearby lymph nodes may be tested for spread. Most people are cured if spread has not occurred. For those in whom melanoma has spread, immunotherapy, biologic therapy, radiation therapy, or chemotherapy may improve survival. With treatment the five-year survival rates in the United States is 98% among those with localized disease and 17% among those in whom spread has occurred. The likelihood that it will come back or spread depends how thick the melanoma is, how fast the cells are dividing, and whether or not the overlying skin has broken down.Melanoma is the most dangerous type of skin cancer. Globally, in 2012, it newly occurred in 232,000 people. In 2015 there were 3.1 million with active disease which resulted in 59,800 deaths. Australia and New Zealand have the highest rates of melanoma in the world. There are also high rates in Northern Europe and North America, while it is less common in Asia, Africa, and Latin America. Melanoma is more common in men than women. Melanoma has become more common since the 1960s in areas which are mostly populated with white people.

Browse All Tags